Current Report Filing (8-k)
2016年9月15日 - 12:37AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest
event reported)
September
14, 2016
IMS Health Holdings, Inc.
(Exact
name of registrant as specified in charter)
Delaware
|
|
001-36381
|
|
27-1335689
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
83 Wooster Heights Road
Danbury, CT 06810
(Address
of Principal Executive Offices, including Zip Code)
(203) 448-4600
(Registrant’s telephone number, including area
code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On September 14, 2016, IMS Health Incorporated (the “Issuer”), a wholly
owned subsidiary of IMS Health Holdings, Inc. (“IMS Health”), entered
into a purchase agreement with the representative of the initial
purchasers named therein, relating to the issuance and sale of $1,750
million equivalent in gross proceeds of the Issuer’s Senior Notes
consisting of (i) $1,050 million of Senior Notes due 2026 bearing
interest at a rate of 5.0% and (ii) €625 million of Senior Notes due
2024 bearing interest at a rate of 3.5%. The net proceeds from the notes
offering (together with proceeds from additional term loans and other
available cash) will primarily be used to extinguish certain existing
indebtedness of the Issuer and Quintiles Transnational Holdings Inc.
(“Quintiles”) in connection with the previously announced proposed
merger between IMS Health and Quintiles. The consummation of the notes
offering is subject to market and other conditions and is mandatorily
redeemable if the merger does not occur.
Item 8.01 Other Events.
On September 14, 2016, IMS Health and Quintiles issued a joint press
release announcing the pricing of the notes offering. A copy of the
press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
99.1 Joint Press Release dated September 14, 2016.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
IMS Health Holdings, Inc.
|
|
|
|
|
By:
|
|
/s/ Ronald E. Bruehlman
|
|
Name:
|
|
Ronald E. Bruehlman
|
|
Title:
|
|
Senior Vice President & Chief Financial Officer
|
Date:
September
14, 2016
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Joint Press Release dated September 14, 2016.
|
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
過去 株価チャート
から 4 2024 まで 5 2024
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
過去 株価チャート
から 5 2023 まで 5 2024
Real-Time news about Ims Health Holdings, Inc. (ニューヨーク証券取引所): 0 recent articles
その他のIms Health Holdings, Inc.ニュース記事